Codon-Optimized Fibrinogen Sequences for Mammalian Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant fibrinogen in mammalian cells result in low expression levels and inadequate purity, making it unsuitable for commercial manufacturing and clinical applications, particularly for intravenous hemostasis where high concentrations and proper post-translational modifications are required.
Innovation Solution
Optimized nucleotide sequences encoding fibrinogen alpha, beta, and gamma chains with enhanced GC content and codon adaptation indices are used to improve expression in mammalian cell culture systems, ensuring high levels of intact, biologically active fibrinogen production without the need for protease inhibitors, leading to homogeneous preparations suitable for clinical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional nucleotide sequences are used for recombinant fibrinogen production in mammalian cells, then expression levels remain low and purity is inadequate, but using optimized sequences increases complexity of the production process
Solution Approach 1:
The patent applies parameter changes by optimizing nucleotide sequences through codon adaptation to mammalian cell preferences and increasing GC content. This transforms the original bacterial nucleotide sequences into optimized versions that are naturally more compatible with mammalian expression systems, thereby increasing fibrinogen expression levels without adding process complexity
Solution Approach 2:
The patent replaces the mechanical approach of using protease inhibitors to prevent degradation with a biological solution - optimizing the nucleotide sequence to produce fibrinogen that is inherently more stable and less susceptible to proteolytic degradation in mammalian cells, thereby achieving high purity without additional chemical additives
2Manufacturing precision
If protease inhibitors are used to maintain fibrinogen integrity, then product purity improves, but production cost and process complexity increase
Solution Approach 1:
The patent extracts and eliminates the need for protease inhibitors from the production process. By optimizing the nucleotide sequence with appropriate codon usage and GC content, the system naturally produces intact fibrinogen without requiring external protease inhibition, thereby simplifying the production process while maintaining high product integrity
Solution Approach 2:
The optimized nucleotide sequence enables the mammalian cell system to self-regulate fibrinogen production and protection. The codon-optimized sequences ensure proper translation efficiency and protein folding, while the increased GC content enhances mRNA stability, allowing the system to maintain fibrinogen integrity through its own biological mechanisms rather than external additives
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.